Honeywell Files Registration Statement for Aerospace Spinoff Planned in 2026
Honeywell filed its Form 10 registration statement with the U.S. Securities and Exchange Commission for the planned spinoff of Honeywell Aerospace, which is slated to begin trading on the Nasdaq under the ticker "HONA" in Q3 of 2026. Meanwhile, MiniMed opened at $19.05 after pricing its 28M‑share initial public offering at $20, below its targeted $25–$28 range.LATEST IPOS AND DIRECT LISTINGS:MiniMedopened on March 6 at $19.05. The diabetes business subsidiary of Medtronicpriced its initial public offering of 28M shares of its common stock at $20.00, below the target range of $25.00-$28.00.Robinhood Ventures Fund Iopened on March 6 at $22 after pricing its initial public offering of 12,615,608 common shares of beneficial interest at an initial public offering price of $25.00 per share. RVI is a closed-end fund from Robinhoodthat provides retail investors exposure to a concentrated portfolio of private companies.PERFORMANCE:Prices as of 10 am ET on Monday, March 9 -MiniMed – up almost 3% at $18.98;Robinhood Ventures Fund I – up 2% at $21.45.RECENT IPOS TO WATCH:ARKO Petroleum, Solv Energy, AGIare already seeing coverage roll out, while Jaguar Uraniumis among stocks that could see new coverage this week as the quiet periods for banks that underwrote the companies' IPOs expire.UPCOMING IPOS:Upcoming IPO and direct listings expected include Studend Living EduVation, Liftoff, Cerebras Systems, PayPay, and OpenAI.Clickto see upcoming IPO calendar on TipRanks.Student Living EduVation -The companyfiled with the SEC for an initial public offering of 3.75M ordinary shares. The company stated, "We are offering 3,750,000 Ordinary Shares on a firm commitment basis. We anticipate that Offering price of the Ordinary Shares will be between $4.00 and $6.00 per Ordinary Share. The Resale Shareholders are also offering 5,880,000 Ordinary Shares to be sold pursuant to the Resale Prospectus. We are registering the Resale Shares pursuant to the Registration Rights Agreements we entered into with the Six Pre-IPO Investors on September 19, 2025... We will not receive any of the proceeds from the sale of the Ordinary Shares by the Resale Shareholders. Prior to this Offering, there has been no public market for our Ordinary Shares. We intend to apply to list our Ordinary Shares on the Nasdaq Capital Market under the symbol 'SDLV'... We are a Cayman Islands exempted company with limited liability with a principal place of business in Hong Kong through our wholly-owned subsidiary, Student Living Culture Technology Limited. We are a student living and referral of education advisory services provider operating under the "Student Living" brand in Hong Kong. Our mission is to transform student dormitories into incubators for learning, collaboration, and self-discovery, as well as fostering an ecosystem that nurtures future global talent, providing more than just a place to live."Liftoff Mobile announced that it has confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The total number of shares to be offered and the price range for the proposed offering have not yet been determined. The offering is subject to market and other conditions and the completion of the SEC's review process.Cerebras Systems– The company has filed confidentially for a U.S. initial public offering, The Information's Valida Pau and Katie Roof. The re-filing comes after a major sales pact with OpenAI, the authors note.PayPay Corporation- The company filed for an initial public offering of American depositary shares, or ADSs, and has applied to list the ADSs on the Nasdaq Global Select Market under the symbol "PAYP." The prospects filed with the SEC states, "As Japan's leading financial technology company, we are dedicated to our goal of becoming a digital finance platform for all... We launched this service in October 2018 and it rapidly expanded to become a nation-wide leading cashless payments ecosystem that had approximately 72 million PayPay registered users as of December 31, 2025, representing a penetration of 75% among 96 million smartphone users in Japan. With the acquisition of PayPay Card Corporation in October 2022, our platform evolved to a next-generation payments ecosystem, seamlessly integrating our code-based payment and credit card payment services through our PayPay app."OpenAI- The is accelerating its plans for a public listing as rivalry with Anthropic intensifies, now planning on listing in Q4 of this year, Berber Jin, Corrie Driebusch, and Kate Clark of The Wall Street Journal. OpenAI is holding discussions with Wall Street banks about a potential initial public offering and has hired several executives to oversee its finance team, sources told the Journal.SpaceX- Elon Musk is targeting mid-June for the timing of SpaceX's initial public offering, IPO, Ivan Levingston, Stephen Morris, and Mercedes Ruehl of The Financial Times, citing five people familiar with the matter. The company is looking to raise $50B at a valuation of $1.5T, the sources added.OTHER IPO NEWS:Honeywellannounced the filing of its Form 10 registration statement with the U.S. SEC for the planned spinoff of Honeywell Aerospace, which will trade on the Nasdaq under the ticker "HONA." The filing represents significant milestone toward Honeywell Aerospace becoming an independent public company in the third quarter of 2026.Opening Day" is The Fly's recurring series of stories on the latest initial public offerings, their performance, and upcoming IPOs.
Trade with 70% Backtested Accuracy
Analyst Views on MMED
About MMED
About the author

- Product Innovation: MiniMed has launched its first MiniMed Flex™ system in the U.S., which is the company's smallest insulin pump to date, representing a significant technological advancement in diabetes management that is expected to enhance patient experience and adherence.
- Smart Control: The system features the Simplera Sync™ sensor, designed for easy two-step insertion and disposable use, aiming to simplify user operations and thereby improve daily management efficiency for diabetes patients.
- Market Potential: The introduction of the MiniMed Flex™ system addresses the U.S. demand for portable and smart insulin pumps, likely attracting more insulin-dependent type 1 and type 2 diabetes patients and further expanding the company's market share.
- Future Plans: MiniMed plans to launch a compatible product with the Instinct sensor made by Abbott later this summer, which will further enhance the competitiveness of its product line and drive ongoing innovation in diabetes management.
- Product Launch: MiniMed has launched its first smart insulin pump, the MiniMed Flex™, in the U.S., which is the company's smallest model yet, capable of holding 300 units of insulin, aimed at providing a more flexible lifestyle for type 1 and insulin-requiring type 2 diabetes patients.
- Technological Innovation: The MiniMed Flex™ system features the Simplera Sync™ sensor with an easy two-step insertion process, while its SmartGuard™ algorithm can automatically adjust insulin delivery every five minutes, helping users maintain 80% Time in Range (TIR).
- Enhanced User Experience: The system is designed to simplify diabetes management in daily life, reducing the number of injections required compared to traditional insulin therapy, allowing users to benefit from up to seven days of wear, significantly improving quality of life.
- Market Potential: The MiniMed Flex™ system is FDA cleared for individuals aged 7 and older with type 1 diabetes and adults aged 18 and older with insulin-requiring type 2 diabetes, which is expected to drive further growth for the company in the diabetes management market.
- REIT Investment Trust: Realty Income (O), a leading real estate investment trust with a market cap of $57 billion, focuses on retail properties and pays a monthly dividend of 5.28%, having increased its payout for over 30 consecutive years, showcasing resilience and appeal amid economic fluctuations.
- Stability of Fast Food Giant: McDonald's (MCD), with over 45,000 locations worldwide, boasts 49 years of annual dividend growth and is on the verge of becoming a Dividend King, with its brand value allowing it to maintain steady revenue during economic downturns, making it attractive for long-term investors.
- Durable Demand for Home Products: Clorox (CLX) holds a significant position in the home products market with its trusted brands, and despite facing high costs and cybersecurity issues, its 48-year dividend growth streak positions it as a potential Dividend King, with the recent acquisition of Purell expected to enhance profitability.
- Long-Term Growth in Healthcare: Medtronic (MDT), a leading global healthcare company with a market cap of $105 billion, is poised for its 50th consecutive annual dividend increase next year, and its expansion into robotic-assisted surgery, along with a projected 6%-7% annual earnings growth, makes it highly attractive in the current market.
- Real Estate Investment Trust: Realty Income (NYSE: O) focuses on retail properties and has increased its dividend for over 30 consecutive years, currently yielding 5.3%, demonstrating stability during economic fluctuations and attracting long-term investors.
- Fast Food Giant: McDonald's (NYSE: MCD) operates over 45,000 locations globally and continues to pay and increase dividends, achieving 49 consecutive years of hikes, positioning it to become a Dividend King and showcasing resilience during economic downturns.
- Household Products Market: Clorox (NYSE: CLX) boasts a 48-year dividend growth streak, and despite facing high costs and cybersecurity issues, it maintains a 5.2% dividend yield, reflecting strong demand for its trusted brands even in economic volatility.
- Healthcare Sector Outlook: Medtronic (NYSE: MDT) is poised for its 50th consecutive dividend increase with a current yield of 3.5%, and its expansion into robotic-assisted surgery and new product launches indicate significant growth potential, making it an attractive option for investors.
- ABIVAX Clinical Trial Success: ABIVAX reported positive results from its Phase 3 ABTECT trial for Obefazimod in ulcerative colitis, achieving primary endpoint of clinical remission at Week 44 with both 25mg and 50mg doses, planning to submit a New Drug Application to the FDA in late Q4 2026, leading to a 24.34% stock increase to $90.15.
- Cingulate Faces FDA Challenge: Cingulate's stock rose 21.09% to $4.88 despite the FDA's rejection of its ADHD drug CTx-1301 application; however, with nearly $30 million in cash reserves, the company aims to resolve CMC issues and proceed with resubmission while continuing pre-commercial activities.
- Alpha Tau Partners with Tolmar: Alpha Tau entered a strategic collaboration with Tolmar to develop and commercialize Alpha DaRT for prostate cancer in the U.S., with Tolmar investing $15 million upfront and $20 million equity stake, while Alpha Tau retains manufacturing rights, resulting in an 18.48% stock increase to $10.58.
- MiniMed Strong Financial Results: MiniMed reported worldwide net sales of $3.102 billion for FY 2026, a 14.2% increase, and expects around 10% organic revenue growth for FY 2027, reflecting strong international market performance and new product launches, with stock rising 15.94% to $14.26.
- Significant Revenue Growth: Minimed Group Inc achieved over $3 billion in revenue for fiscal 2026, reflecting an 8% increase, with international revenue growing by 12.2%, indicating strong performance in global markets that is expected to enhance future market share.
- Substantial EBITDA Increase: The company reported an adjusted standalone EBITDA of $154 million in Q4, representing 18.4% of revenue and a 32% year-over-year growth, demonstrating significant operational efficiency improvements that bolster investor confidence.
- New Products Driving Future Growth: The launch of new products such as MiniMed Flex, MiniMed Go, and the Instinct sensor is anticipated to drive future sales growth, particularly in international markets, further solidifying the company's market leadership.
- Optimistic FY27 Outlook: The company projects approximately 10% organic growth for fiscal 2027, especially in the U.S. market, where sales and market penetration are expected to increase progressively with the introduction of new products, reflecting management's confidence in future performance.











